Made In China, Sold In India: Cipla’s First Splash In Biosimilars Is A Cut Price Version Of Enbrel
This article was originally published in PharmAsia News
Executive Summary
The homegrown Indian drug manufacturer will sell its drug 30% cheaper than Amgen’s product and aims to capture significant share of the market.